Avenge Bio

Avenge Bio

  • Founded: 2019
  • Location: Natick, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Peritoneal cancers
  • Drug types: ONC
  • Lead product: AVB-001
  • Product link: https://avengebio.com/#technology-pipeline
  • Funding: $45M A Jan 2022



job board

Short description:

Cell & Gene Therapies

Drug notes:

Also Clin0 lung cancers; AVB-002 Clin0 multiple cancers; AVB-003 RD undisclosed; 2 undisclosed programs RD undisclosed

Long description:

Avenge Bio is developing immunotherapies to eradicate intractable solid tumors. Building an effective immune response is one strategy to eliminate cancer cells. Avenge’s approach to attain this involves their proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines. Cytokines generate a robust, local and systemic anti-tumor immune response, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform identifies potent immune effector molecules that can be used for localized modulation of the immune system. Avenge’s lead candidate, ABV-001, is an encapsulated cell product engineered to produce the cytokine IL-2 and is in clinical trials for patients with serous adenocarcinoma.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com